1. Home
  2. PDC vs NSRX Comparison

PDC vs NSRX Comparison

Compare PDC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$7.10

Market Cap

23.7M

Sector

Technology

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$2.79

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDC
NSRX
Founded
2018
2019
Country
Japan
Israel
Employees
20
7
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
25.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PDC
NSRX
Price
$7.10
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
130.1K
126.7K
Earning Date
07-01-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$1.98
52 Week High
$8.40
$9.99

Technical Indicators

Market Signals
Indicator
PDC
NSRX
Relative Strength Index (RSI) 48.62 43.62
Support Level $4.48 $2.41
Resistance Level $7.90 $3.48
Average True Range (ATR) 0.77 0.28
MACD -0.20 -0.02
Stochastic Oscillator 39.31 9.89

Price Performance

Historical Comparison
PDC
NSRX

About PDC Perpetuals.com Ltd American Depositary Shares

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: